ASX:TLXBiotechs
Does Asian TLX591-Px Expansion Progress Change The Bull Case For Telix Pharmaceuticals (ASX:TLX)?
Telix Pharmaceuticals reported that China’s NMPA has accepted the New Drug Application for its prostate cancer imaging agent TLX591-Px (Illuccix®), supported by a pivotal Phase 3 study in Chinese patients with biochemical recurrence.
In parallel, the first patient has now been dosed in a Phase 3 registration study in Japan, highlighting Telix’s push to expand TLX591-Px across major Asian nuclear medicine markets in prostate cancer care.
We’ll next examine how this progress toward broader...